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ABSTRACT Although uncontrolled inflammatory re-
sponse plays a central role in the pathogenesis of acute
lung injury (ALI), the precise molecular mechanisms
underlying the development of this disorder remain
poorly understood. SOCS3 is an important negative
regulator of IL-6-type cytokine signaling. SOCS3 is
induced in lung during LPS-induced lung injury, sug-
gesting that generation of SOCS3 may represent a
regulatory product during ALI. In the current study, we
created mice lacking SOCS3 expression in macro-
phages and neutrophils (LysM-cre SOCS3fl/fl). We eval-
uated the lung inflammatory response to LPS in both
LysM-cre SOCS3fl/fl mice and the wild-type (WT) mice
(SOCS3fl/fl). LysM-cre SOCS3fl/fl mice displayed signif-
icant increase of the lung permeability index (lung
vascular leak of albumin), neutrophils, lung neutrophil
accumulation (myeloperoxidase activity), and proin-
flammatory cytokines/chemokines in bronchial alveo-
lar lavage fluids compared to WT mice. These pheno-
types were consistent with morphological evaluation of
lung, which showed enhanced inflammatory cell influx
and intra-alveolar hemorrhage. We further identify the
transcription factor, CCAAT/enhancer-binding protein
(C/EBP)  as a critical downstream target of SOCS3 in
LPS-induced ALI. These results indicate that SOCS3
has a protective role in LPS-induced ALI by suppressing
C/EBP activity in the lung. Elucidating the function of
SOCS3 would represent prospective targets for a new
generation of drugs needed to treat ALI.—Yan, C.,
Ward, P. A., Wang, X., Gao, H. Myeloid depletion of
SOCS3 enhances LPS-induced acute lung injury
through CCAAT/enhancer binding protein  pathway.
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Suppressor of cytokine signaling 3 (SOCS3) inhibits
STAT/JAK signaling by either mediating cytokine re-
ceptor/JAK degradation or inhibiting JAK catalytic
activity. SOCS3 expression can be induced by a
variety of stimuli, including cytokines, Toll-like recep-
tor (TLR) ligands, bacteria, and immune complexes
(1–3). SOCS3 can be activated by LPS in both neutro-
phils and macrophages (4–6). Of note, SOCS3 is one
of the most abundantly induced proteins in LPS-treated
macrophages (4). The role of SOCS3 in inflammation
has been studied in both innate and adaptive immune
cells. Both pro- and anti-inflammatory functions of
SOCS3 have been reported. For example, IL-6 pro-
motes both in vivo acute and chronic inflammation in
the absence of SOCS3 (7). In addition, SOCS3 plays a
key role in regulating IFN--like responses induced by
IL-6 (8, 9). Of note, SOCS3 overexpression mitigates
inflammatory arthritis induced by antigen/IL-1 or
collagen, as well as acute inflammation induced by
staphylococcal enterotoxin B and LPS (10–13). In
contrast with the above findings, myeloid SOCS3-
deficient mice are shown to be resistant to LPS-induced
shock (14, 15). This result indicates that SOCS3 may
function as a proinflammatory mediator (14, 15). Sup-
porting this hypothesis, Liu et al. (16) show that SOCS3
inhibits the TGF1/Smad3 signaling pathway, which
leads to enhancing TLR4-mediated inflammatory re-
sponse in macrophages. Recently, it has been shown
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that both T-cell-specific SOCS3-deficient mice and
transgenic mice overexpressing the SOCS3 gene in T
cells are susceptible to infection by Leishmania major
(17, 18). Based on these studies, targeting SOCS3
signaling pathway may offer an attractive strategy for
preventing or resolving inflammation associated with
various diseases.
The role of SOCS3 in the lung has also been inves-
tigated. Enhanced SOCS3 expression in T cells has
been linked to the onset and maintenance of human
allergic diseases (19). Moreover, a recent study shows
that treatment of T cells with SOCS3-specific siRNA
significantly suppresses airway responses in a murine
model of ovalbumin (OVA)-induced allergic asthma
(20). Data for SOCS3 in acute lung injury (ALI) are
limited. Our previous work demonstrates that adenovi-
rus-mediated overexpression of SOCS3 enhances IgG
immune complex-induced lung injury (2). A recent
study suggests a link between SOCS3 and acid-induced
ALI in mice (21). However, due to the embryonic
lethality of SOCS-knockout (KO) mice (22), the func-
tion of SOCS3 in ALI remains to be established. In this
report, we used myeloid-specific SOCS3-KO mice to
demonstrate for the first time that SOCS3 deficiency
significantly enhances acute lung inflammation and
injury induced by intratracheal LPS administration.
Moreover, our data implicate the transcription factor
CCAAT/enhancer-binding protein (C/EBP)  as a critical
downstream target of SOCS3 in LPS-induced ALI.
MATERIALS AND METHODS
Animals, cells, and reagents
Specific pathogen-free male C57BL/6 mice, SOCS3fl/fl mice,
and LysM-cre mice expressing Cre recombinase from the
endogenous lysozyme M locus were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA), and maintained
in a specific pathogen-free facility. Conditional SOCS3-KO
mice that lack SOCS3 in myeloid (LysM-cre SOCS3fl/fl) were
generated as described previously (14), and all mice were
used at the age of 8–12 wk old. Generation of C/EBP/
and C/EBP/ mice by homologous recombination has
been described previously (23, 24). Mouse alveolar macro-
phage-derived cell line, MH-S, was purchased from American
Type Culture Collection (Manassas, VA, USA), and cultured
in RPMI 1640 medium supplemented with 10% fetal bovine
serum, 2 mM l-glutamine, 100 U/ml penicillin, 100 g/ml
streptomycin and 0.01 M HEPES, and maintained in a
humidified incubator at 37°C with 5% CO2. ELISA kits for
mouse IL-6, TNF-, macrophage inflammatory protein 2
(MIP-2), and keratinocyte-derived chemokine (KC) were ob-
tained from R&D Systems (Minneapolis, MN, USA).
LPS-induced ALI
All procedures involving mice were approved by the Animal
Care and Use Committee of Harvard Medical School. Mice
were anesthetized intraperitoneally with ketamine HCl (100
mg/kg), followed by intratracheal instillation of 50 l of LPS
dissolved in phosphate-buffered saline (PBS; 1 mg/ml) dur-
ing inspiration. Negative control mice received 50 l PBS
intratracheally. Unless otherwise indicated, mice were exsan-
guinated 18 h after LPS deposition, and the pulmonary
circulation was flushed with 1 ml of PBS via the pulmonary
artery. The lungs were immediately frozen in liquid nitrogen.
Myeloperoxidase (MPO) activity
Lungs were perfused via the right ventricle with 3 ml of PBS.
For MPO activity, the lungs were homogenized in 50 mM
potassium phosphate buffer containing 0.5% hexadecyltrim-
ethylammonium bromide and 5 mM EDTA. The samples
were sonicated for 1 min, and centrifuged at 10,000 rpm for
10 min. Next, 10 l of the recovered supernatants was added
to a 96-well plate, followed by addition of 100 mM potassium
phosphate buffer containing 1.5 M H2O2 and 167 g/ml
o-dianisidine dihydrochloride. The enzyme activity was deter-
mined by measuring the change in optical density (OD) at
450 nm over a period of 4.5 min using a 96-well plate reader.
Histological assay
At 18 h after LPS deposition, 1 ml of 10% buffered (pH 7.2)
formalin was instilled into the lung via the trachea. The lungs
were then surgically removed and further fixed in 10%
buffered formalin solution for morphological assay by tissue
sectioning and staining with hematoxylin and eosin (H&E).
Bronchial alveolar lavage (BAL) fluid collection, differential
white blood cell counts, albumin, and chemokine/cytokine
ELISAs
At 18 h after initiation of the ALI, the thorax was opened, and
0.8 ml of ice-cold, sterile PBS was instilled into the lung via a
tracheal incision. The recovered BAL fluid was centrifuged at
450 g for 6 min, and the cell-free supernatants were used for
chemokine and cytokine measurements by ELISAs. Cell pel-
lets were resuspended in 1 ml of Hanks balanced salt solution
(HBSS) containing 0.5% bovine serum albumin (BSA), and
differential cell analyses were performed by Diff-Quik-stained
cytospin preparations (Dade, Duedingen, Switzerland) count-
ing a total of 300 cells/slide in randomly selected high-power
fields (1000). Mouse albumin levels in BAL fluid were
measured using a mouse albumin ELISA kit (Bethyl Labora-
tories, Montgomery, TX, USA). The permeability index was
expressed as the ratio of the albumin in the LPS-injured lungs
vs. that in the control-treated lungs of same type of mice.
Alveolar macrophage isolation and culture
Mouse lungs were lavaged 3 times with ice-cold PBS. BAL
fluids were then centrifuged at 1000 rpm for 10 min, and cell
pellets were suspended in Dulbecco’s modified Eagle me-
dium supplemented with 5% fetal bovine serum. Next, 1.5 
104 cells were seeded in each well of 96-well plate. After 2 h,
the medium was removed, and the cells were challenged with
100 ng/ml LPS for indicated time periods. Supernatants were
harvested to conduct ELISA.
Assessment of C/EBP activation by electrophoretic mobility
shift assay (EMSA)
Lung nuclear extracts were prepared as described previously
(21). Briefly, frozen lungs were homogenized in 0.6% (v/v)
Nonidet P-40, 150 mM NaCl, 10 mM HEPES (pH 7.9), 1 mM
EDTA, 0.5 mM phenylmethylsulfonyl fluoride, 2.5 g/ml
leupeptin, 5 g/ml antipain, and 5 g/ml aprotinin. The
homogenate was incubated on ice for 5 min and then
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centrifuged for 5 min at 5000 g at 4°C. Proteins were
extracted from the pelleted nuclei by incubation at 4°C with
solution B (420 mM NaCl; 20 mM HEPES, pH 7.9; 1.2 mM
MgCl2; 0.2 mM EDTA; 25% (v/v) glycerol; 0.5 mM dithio-
threitol; 0.5 mM phenylmethylsulphonyl fluoride; 2.5 g/ml
leupeptin; 5 g/ml antipain; and 5 g/ml aprotinin). Nu-
clear debris was pelleted by centrifugation at 13,000 g for 30
min at 4°C, and the supernatant extract was collected and
stored at 80°C. The EMSA probes were double-stranded
oligonucleotides containing a C/EBP consensus oligonucle-
otide (5=-TGCAGATTGCGCAATCTGCA-3=; Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA). C/EBP probes were
labeled with [32P] ATP (3000 Ci/mmol at 10 mCi/ml;
Amersham Biosciences Corp, Sunnyvale, CA, USA). DNA
binding reactions were performed at room temperature in a
25-l reaction mixture containing 6 l of nuclear extract
(1 mg/ml in buffer C or solution B) and 5 l of 5 binding
buffer (20% (w/v) Ficoll; 50 mM HEPES, pH 7.9; 5 mM
EDTA; and 5 mM dithiothreitol). The remainder of the
reaction mixture contained KCl at a final concentration of 50
mM, Nonidet P-40 at a final concentration of 0.1%, 1 g of
poly(dI-dC), 200 pg of probe (unless otherwise noted),
bromphenol blue at a final concentration of 0.06% (w/v),
and water to volume of 25 l. Samples were electrophoresed
through 5.5% polyacrylamide gels, dried under vacuum, and
exposed to X-ray film. For supershifts, nuclear extracts were
preincubated with antibodies (1–2 g) for 0.5 h at 4°C prior
to the binding reaction. The following antibodies were pur-
chased from Santa Cruz Biotechnology: C/EBP, C/EBP,
and normal rabbit immunoglobulin G.
Luciferase assay
MH-S cells were transfected with indicated reporter plasmids
by using Fugene6 transfection reagent (Roche, Indianapolis,
IN, USA). At 48 h after transfection, cells were treated with or
without 100 ng/ml LPS. After 4 h, cells were lysed in Passive
Lysis 5X buffer (Promega, Madison, WI, USA), and luciferase
activity was measured. Mouse SOCS3 expression plasmids
were described previously (25). The reporter plasmid con-
taining 2 copies of a C/EBP binding site, 2  C/EBP-Luc, the
mouse IL-6 promoter-reporter, and TNF- promoter-re-
porter, as well as the C/EBP expression plasmid, have been
described in our previous publications (26, 27).
RNA isolation and detection of SOCS3 mRNA by real-time PCR
Total RNAs were extracted from lungs with Trizol (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
procedure. Total RNA (2 g) was submitted to reverse
transcription by using the Superscript II RNase H- Reverse
Transcriptase (Invitrogen). PCR was performed with primers
for SOCS3: 5= primer, 5=-AGCTCCAAAAGCGAGTACCA-3=,
and 3= primer, 5=-TGACGCTCAACGTGAAGAAG-3=. Follow-
ing reverse transcription, the cDNA was amplified and quan-
tified using a Sequence Detection System (SDS 7300; Invitro-
gen) and a PCR universal protocol as follows: AmpliTaq Gold
(Invitrogen) activation at 95°C for 15 s and annealing/
extension at 60°C for 1 min. The fluorescence of the double-
stranded products accumulated was monitored in real time.
The relative mRNA levels were normalized to levels of
GAPDH mRNA in the same sample.
Statistical analysis
All values are expressed as means  se. Data sets were
analyzed using Student’s t test or 1-way ANOVA, with individ-
ual group means being compared with the Student-Newman-
Keuls multiple comparison test.
RESULTS
Effect of myeloid SOCS3 deficiency on LPS-induced ALI
Alveolar macrophages are critical for initiation of the
LPS-induced innate immune response in the lung (28).
We generated LysM-cre SOCS3fl/fl mice, which lack
SOCS3 expression in macrophages and neutrophils
(14). To examine the role of SOCS3 in LPS-induced
inflammation in vivo, SOCS3fl/fl and LysM-cre SOCS3fl/fl
mice were intratracheally injected with LPS to mimic human
gram-negative ALI. We investigated whether myeloid-specific
depletion of SOCS3 affected pulmonary vascular permeabil-
ity by measuring albumin levels in BAL fluids. LPS deposi-
tion led to an obvious increase in lung vascular permeability
(Fig. 1A). Notably, permeability index was significantly aug-
mented in LysM-cre SOCS3fl/fl mice challenged with LPS
when compared to their WT littermates (SOCS3fl/fl; Fig.
1A). We further examined lung MPO content, which reflects
the number of neutrophils recruited into the lung (Fig. 1B).
MPO activity in lung homogenates was greatly elevated in
LPS-injured mice compared with noninflamed mice (Fig.
1B). As with pulmonary vascular permeability, lung MPO
activity was markedly increased in LysM-cre SOCS3fl/fl mice
when compared with SOCS3fl/fl mice during LPS-induced
acute lung inflammation (Fig. 1B). We next determined the
total leukocyte and neutrophil counts in BAL fluids, which
contributed to lung damage. As shown in Fig. 2A, in the
Control LPS
0
1
2
3
4
SOCS3fl/fl
LysM-cre SOCS3fl/fl
p<0.05
P
er
m
ea
bi
lit
y 
in
de
x
Control LPS
0
250
500
750
1000
SOCS3fl/fl
LysM-cre SOCS3fl/fl
p<0.05
M
P
O
 a
ct
iv
ity
  (
pe
r g
ra
m
 lu
ng
)
A B
Figure 1. Effects of myeloid deletion of SOCS3
on LPS-induced ALI. SOCS3fl/fl and LysM-cre
SOCS3fl/fl mice received airway injection of
LPS. After 18 h, BAL fluids and whole lungs
were harvested. A) Mouse albumin content in
BAL fluids was determined using ELISA as an
index of lung microvascular permeability.
B) Changes in lung MPO activity were mea-
sured as an index of lung neutrophil accumu-
lation. Data are expressed as means  se; n 	 3,
control-treated groups; n 	 5–6, injured groups.
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presence of LPS, the number of total leukocytes recovered
from BAL fluids was markedly elevated as compared with
control mice received PBS alone. In inflamed lungs, the
major cells present in BAL fluids were neutrophils (Fig. 2).
Notably, LysM-cre SOCS3fl/fl mice exhibited enhanced re-
cruitment of total leukocytes and neutrophils into alveolar
spaces as compared with SOCS3fl/fl mice during LPS-
induced ALI (Fig. 2). Therefore, SOCS3 expression in
myeloid-derived cells mitigated lung injury by suppression of
leukocytes, especially neutrophils recruited into airway
spaces in the LPS-induced acute lung inflammation model.
To further evaluate the effect of SOCS3 on LPS-
induced ALI, we performed histological assays. As shown
in Fig. 3A, B, mice treated with PBS exhibited normal
pulmonary architecture without evidence of inflamma-
tory features. Mice receiving airway administration of LPS
showed lung hemorrhage, edema, and neutrophil accu-
mulation (Fig. 3C). Notably, all of these features were
significantly enhanced in LPS-challenged mice lacking
SOCS3 (Fig. 3D). Taken together, these data indicate that
depletion of SOCS3 expression in myeloid-derived cells
enhances LPS-induced acute lung inflammation by in-
creasing the permeability index and neutrophil accumu-
lation.
Effect of myeloid SOCS3 deficiency on
cytokine/chemokine expressions in LPS-injured lung
We determined the influence of SOCS3 on proinflamma-
tory cytokine/chemokine production in BAL fluids har-
vested 18 h after intratracheal administration of LPS. As
shown in Fig. 4, in the absence of LPS, there were only
very low levels of inflammatory mediators in BAL fluids
collected from either SOCS3fl/fl or LysM-cre SOCS3fl/fl
mice, and LPS challenge significantly induced TNF-,
IL-6, KC, and MIP-2 production. Notably, in LPS-injured
lungs, myeloid-deletion of SOCS3 resulted in a significant
increased expression of TNF- (Fig. 4A), IL-6 (Fig. 4B),
KC (Fig. 4C), and MIP-2 (Fig. 4D) by 97, 77, 147, and
128%, respectively, when compared with WT mice, indi-
cating that SOCS3 expression in myeloid cells might play
a central role in cytokine and chemokine generation
during LPS-induced ALI. Our previous study indicates
that SOCS3 overexpression has a positive regulatory role
in IgG immune complex-induced lung inflammatory re-
sponse (2). We next determined the influence of SOCS3
deficiency on proinflammatory cytokine/chemokine pro-
duction in BAL fluids harvested 4 h after IgG immune
complex deposition in the lung. As shown in Supplemen-
tal Fig. S1, IgG immune complex deposition significantly
induced TNF-, IL-6, KC, and MIP-2 production in the
BAL fluids collected from SOCS3fl/fl mice. In contrast to
the LPS model (Fig. 4), SOCS3 deficiency (LysM-cre
SOCS3fl/fl) resulted in a significantly decreased produc-
tion of TNF-, IL-6, KC, and MIP-2 in IgG immune
complex-injured lungs, when compared with SOCS3fl/fl
mice (Supplemental Fig. S1). Furthermore, SOCS3 defi-
ciency resulted in a significant decrease in production of
TNF- from IgG immune complex-stimulated alveolar
macrophages, when compared with cells from SOCS3fl/fl
mice (Supplemental Fig. S2). These data together sug-
gest that SOCS3 plays an opposite role in the LPS-
and IgG immune complex-induced lung inflamma-
tory responses.
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Figure 2. Effects of myeloid deletion of SOCS3
on leukocyte counts in BAL fluid from
LPS-injured lungs. SOCS3fl/fl and LysM-cre
SOCS3fl/fl mice received airway injection of
LPS. After 18 h, BAL fluids and whole lungs
were harvested. Total leukocytes (A) and neu-
trophils (B) in BAL fluids were quantitated.
Data are expressed as means  se; n 	 3,
control-treated groups; n 	 5–6, injured
groups.
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Figure 3. Effects of myeloid deletion of SOCS3 on lung
histology during LPS-induced lung injury. SOCS3fl/fl and
LysM-cre SOCS3fl/fl mice received airway injection of LPS.
Sections from lungs harvested 18 h after PBS or LPS deposition
in SOCS3fl/fl and LysM-cre SOCS3fl/fl mice were stained with
H&E (40 view). Lung sections shown include SOCS3fl/fl 

PBS (A), LysM-cre SOCS3fl/fl 
 PBS (B), SOCS3fl/fl 
 LPS (C),
and LysM-cre SOCS3fl/fl 
 LPS (D). Scale bars 	 60 m.
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SOCS3 negatively regulates LPS-induced production
of inflammatory mediators in alveolar macrophages
SOCS3 expression is induced by LPS in many cell types,
including peritoneal macrophages, neutrophils, osteo-
blasts, and microglia (6, 14, 29, 30). To determine
whether SOCS3 expression can be induced in alveolar
macrophages, we challenged MH-S cells with LPS for
different time periods, and conducted real-time PCR
experiments. As shown in Fig. 5A, SOCS3 mRNA ex-
pression was dramatically induced by LPS at 2 and 4 h
time points, and thereafter, its expression was gradually
decreased. Next, we sought to investigate the role of
SOCS3 in LPS-induced inflammation in alveolar mac-
rophages. As shown in Fig. 5B, C, LPS treatment
stimulated TNF- and IL-6 promoter-driven luciferase
expression by 2- and 13-fold, respectively. Further-
more, overexpression of SOCS3 decreased LPS-induced
TNF- and IL-6 reporter expression by 45 and 30%,
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Figure 4. Effects of SOCS3 deficiency on LPS-induced production of cytokines
and chemokines in BAL fluids. BAL fluids were harvested 18 h after onset of
LPS-induced lung injury in SOCS3fl/fl and LysM-cre SOCS3fl/fl mice. ELISAs were
performed to determine the levels of TNF- (A), IL-6 (B), KC (C), and MIP-2 (D)
in BAL fluids. Results are means  se; n 	 3, control group; n 	 5–6,
LPS-challenged group.
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Figure 5. Effects of SOCS3 expression on LPS-induced TNF- and IL-6 expression in alveolar macrophage cells. A) MH-S cells
were treated with 100 ng/ml LPS for indicated time periods. Total cellular RNAs were extracted and subjected to real-time PCR
for the expression of SOCS3 and GAPDH. Data are expressed as means  se (n	3). B, C) Transient transfections were
performed in MH-S cells by using 0.5 g of indicated DNA. After 48 h, the cells were treated with or without 100 ng/ml LPS
for 4 h. TNF- (B) and IL-6 (C) luciferase activity was measured. Luminometer values were normalized for expression from a
cotransfected thymidine kinase reporter gene. These values were then normalized to a relative value of 1 for the control plasmid
transfected cells that was not stimulated by LPS. Data are expressed as means  se (n	3).
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respectively. Next, we isolated primary alveolar macro-
phages from SOCS3fl/fl and LysM-cre SOCS3fl/fl mice and
treated these cells with LPS for various times. As shown in
Fig. 6, SOCS3-deficient alveolar macrophages released
significantly higher levels of TNF-, IL-6, KC, and MIP-2 at
all time points after LPS treatment compared to SOCS3-
proficient cells. Taken together, these data indicated that
SOCS3 negatively regulates TLR4-mediated inflammation
in alveolar macrophages.
SOCS3 regulates C/EBP and  activity in LPS-injured
lung and alveolar macrophages stimulated with LPS
The C/EBPs (C/EBP, -, -, -ε, -, and -) comprise a
family of basic region-leucine zipper (bZIP) transcription
factors that dimerize through a leucine zipper and bind to
DNA through an adjacent basic region (31–33). Among
them, C/EBP and C/EBP are regulators of proinflam-
matory cytokines, as well as other gene products of the
acute-phase response (32, 34–40). C/EBP has 2 major
isoforms: liver-enriched activating protein (LAP) and its
short isoform, liver-enriched inhibiting protein (LIP),
which is translated from an alternative start site in the
same messenger RNA (41). Our recent studies demon-
strated that the binding activities of both C/EBP and
C/EBP were significantly induced in LPS-injured lungs
(42). Notably, C/EBP, but not C/EBP, is a key regula-
tor of LPS-induced lung injury (42). We sought to deter-
mine whether SOCS3 regulates LPS-induced C/EBP
and C/EBP activation in the lung. As shown in Fig. 7A, B,
DNA-binding activity of lung C/EBP and C/EBP was
significantly higher in LysM-cre SOCS3fl/fl mice than in
SOCS3fl/fl mice. We also assessed the role of SOCS3 in
regulating C/EBP activity in alveolar macrophages by
performing reporter assays using 2C/EBP-Luc, a pro-
moter-reporter whose expression is driven by 2 copies of a
C/EBP binding site. MH-S cells (an alveolar macrophage
cell line) were transiently transfected with 2C/EBP-Luc
in the presence or absence of a SOCS3-expressing plas-
mid. As shown in Fig. 7C, LPS treatment caused a
2.5-fold increase in luciferase activity. Notably, ectopic
expression of SOCS3 led to a significant decrease in
LPS-induced luciferase activity (Fig. 7C). In contrast,
although we observed 8-fold LPS induction of NF-B-
luciferase expression, this activity was not inhibited by
SOCS3 (data not shown). To further evaluate the influ-
ence of SOCS3 on C/EBP-driven 2C/EBP-Luc expres-
sion, we transiently transfected MH-S cells with 2C/EBP-
Luc in the presence or absence of C/EBP expression
plasmid. As shown in Fig. 7D, C/EBP expression resulted
in a 1.6-fold increase of 2C/EBP-Luc luciferase activity,
while SOCS3 decreased luciferase expression to basal levels.
To further establish a functional link between C/EBP
and SOCS3 in LPS-stimulated macrophages, we trans-
fected MH-S cells with TNF- or IL-6 promoter-driven
luciferase constructs in the presence or absence of a
SOCS3- and/or C/EBP-expressing plasmids. As ex-
pected, expression of SOCS3 led to a significant decrease
in LPS-induced luciferase activity (Fig. 8). Notably, over-
expression of C/EBP significantly reversed SOCS3-medi-
ated inhibition of the luciferase expression (Fig. 8).
Taken together, these data suggest that C/EBP is a
critical target of SOCS3 in the TLR4 pathway.
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DISCUSSION
Despite the recent development of protective lung
ventilation strategies, ALI and its severe form, acute
respiratory distress syndrome (ARDS), remain leading
factors of morbidity and mortality in critically ill pa-
tients (43–46). One of the major cellular responses in
lung initiated by various direct and indirect stimuli is
the activation of genes encoding various inflammation-
associated mediators. While a variety of factors, such as
acute-phase proteins, lipid metabolites, coagulation fac-
tors, and antimicrobial peptides, are involved in the
acute lung inflammatory response, cytokines constitute
the largest and most pleiotropic group of such media-
tors (47). The critical role that cytokines play in the
initiation, maintenance, and resolution of lung inflam-
mation has been well recognized. For example, along
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with other soluble factors, as well as adhesion mole-
cules, the cytokines contribute to the recognition of
pathogens, the recruitment of neutrophils and mono-
nuclear cells, and the removal of the invading micro-
organism (47). Accordingly, the levels of pro- and
anti-inflammatory cytokines and their balance deter-
mine the magnitude of lung inflammation and out-
come. An imbalance in the cytokine response may
result in an uncontrolled systemic inflammatory re-
sponse such as sepsis or allow progression of the
infection, both of which often leads to organ dysfunc-
tion. Understanding how the inflammatory process in
the lung is activated and how it is contained are key to
developing strategies designed to block or reduce lung
injury (48). Thus, the biological events and detailed
molecular mechanisms that regulate the progression
and resolution of inflammation in the lung remain of
interest. In vivo animal model of LPS-induced ALI are
widely used as experimental approaches to study the
mechanisms of acute lung inflammation, which displays
key features of microvascular injury as seen in patients
with ARDS (49). Using this model, a recent study
demonstrates that inhibiting Mer receptor tyrosine
kinase suppresses STAT1, SOCS1/3, and NF-B activa-
tion and enhances inflammatory responses in LPS-
induced ALI (50). However, the exact role of SOCS3 in
ALI and the underlying molecular mechanisms remain
unknown. In the current study, we show that myeloid-
specific SOCS3 deficiency significantly inhibits LPS-
induced ALI as defined by enhanced albumin leakage
into lung, MPO content, and histology change in the
lung, suggesting that SOCS3 is a critical mediator of
LPS-induced ALI and inflammatory response in alveo-
lar macrophages.
The mechanisms whereby SOCS3 regulates cytokine
signaling have been extensively studied. SOCS3 inhibits
cytokine receptors/Janus kinases (JAKs)/STATs activi-
ties by either directly inhibiting the catalytic activity of
JAK1/2/TYK2 or mediating ubiquitination of JAKs and
cytokine receptors targeting them for proteasomal deg-
radation (51). In addition, a recent study shows that
SOCS3 interacts with both JAK and the gp130 receptor
simultaneously, suggesting that SOCS3 at physiological
level exerts its inhibitory function through cytokine
receptors with SOCS3 binding sites (52). In contrast,
the mechanism of how SOCS3 suppresses LPS-induced
gene expression is still unclear. Both direct and indirect
mechanisms have been proposed. SOCS3 has been
shown to be the dominant mediator of the anti-inflam-
matory effects of IL-10 in macrophages (30, 53), sug-
gesting a direct role of SOCS3 in mediating the anti-
inflammatory response. The effect of SOCS on TLR
signaling has also been proposed to occur indirectly
through STAT3 activation (54). However, the target
genes of SOCS3 necessary for this suppression are not
known.
While our previous study shows that adenoviral-
mediated overexpression of SOCS3 enhances IgG im-
mune complex-induced ALI (2), the current study
shows that SOCS3 negatively regulates TLR4 signaling
in the lung. This duality of function suggests a new
paradigm for SOCS3 in inflammatory response and
lung injury. Of note, the duality of function is an
emerging paradigm for not only SOCS3 but also many
other immune mediators. For example, TLR4 agonists
have opposing actions on lung function depending on
the dose and timing of their administration (55). This
study shows that low-level inhaled LPS signaling
through TLR4 is necessary to induce Th2 responses to
inhaled antigens in a mouse model of allergic sensiti-
zation. In contrast to low levels, inhalation of high
levels of LPS with antigen results in Th1 responses. In
another study, Cao et al. (56) show that the inositol
3-phosphatase PTEN negatively regulates FcR signal-
ing, but supports TLR4 signaling in murine peritoneal
macrophages. Using the same SOCS3 myeloid-KO
mice, we found that SOCS3 deficiency led to a signifi-
cant decrease of IgG immune complex-induced cyto-
kine and chemokine production in the BAL fluids
(Supplemental Fig. S1). These data together suggest
that SOCS3 is a negative regulator of TLR4 signaling
but a positive regulator of FcR signaling in the lung. In
addition, the role of SOCS3 during lung inflammation
remains largely unknown and is likely to be complex.
In the present study, we show that both C/EBP and
C/EBP activation in the LPS-injured lung were signif-
icantly higher in myeloid-specific SOCS3-KO mice than
in WT mice (Fig. 7), implicating C/EBP and/or
C/EBP as possible targets of SOCS3 in the lung.
Indeed, our recent study using C/EBP-deficient mice
demonstrates that C/EBP is a critical mediator of
acute inflammatory responses in LPS-injured lung and
alveolar macrophages stimulated by LPS (42). Interest-
ingly, we found that C/EBP deficiency had no effect
on LPS-induced lung injury (42). These findings to-
gether indicate for the first time that C/EBP transcrip-
tion factor is a key target of SOCS3 in LPS-induced lung
inflammatory responses and injury. Several studies have
shown that C/EBP and C/EBP play important roles
in regulating inflammatory function (32, 57). The fact
(57) that knocking down either C/EBP or C/EBP
has no effect on LPS-induced IL-6 and TNF- produc-
tion in peritoneal macrophages, while the absence of
both C/EBP and C/EBP results in a significant
decrease in IL-6 and TNF- expression, indicates a
functional redundancy for these two transcription fac-
tors. In contrast, our recent finding (42) that C/EBP
is a key regulator of LPS-induced inflammation in
alveolar macrophages suggests that the function of
C/EBP is cell-specific. Although both C/EBP and
C/EBP can bind the same promoter regions of several
inflammatory mediators, including IL-6 and TNF-,
their distinct transactivation domains may contribute
the unique functions in different cells and/or tissues.
Of note, while in the current study we provide the first
evidence that SOCS3 inhibited C/EBP DNA binding
activity induced by LPS, the same treatment did not
affect NF-B activation (Fig. 7 and data not shown).
NF-B has been proven to play a key role in the
transcriptional up-regulation of many of the LPS-in-
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duced inflammatory mediators. Hence, our study sug-
gests that NF-B itself is not sufficient to mediate
inflammatory mediator expression, which may require
its interaction with other transcription factors such as
C/EBPs for LPS induction of these genes.
Activated alveolar macrophages play an indispens-
able role in LPS-induced lung inflammatory responses
(28). In the current study we show that SOCS3 defi-
ciency in alveolar macrophages results in a dramatic
enhancement of LPS-induced cytokine and chemokine
production (Fig. 6). Based on our results, we propose a
novel SOCS3-C/EBP pathway in the LPS-injured lung,
which encourages further evaluation of their therapeu-
tic potential for the treatment of ALI.
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